Remy Lamberts
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for urology clinicians in NV, where the typical reported total is $2,990.
Across 62 payments — averaging $41.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$607
- Neotract Inc.$454
- Boston Scientific$307
- Urogen Pharma, Inc.$262
- AbbVie$166
- Astellas Pharma US Inc$150
- plus $623 from 10 others
What the payments were for
- Food & beverage$2,41994%
- Education$1516%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 12 | $607 |
| Neotract Inc. | 9 | $454 |
| Boston Scientific | 11 | $307 |
| Urogen Pharma, Inc. | 4 | $262 |
| AbbVie(2 entities) | 8 | $166 |
| Astellas Pharma US Inc | 2 | $150 |
| Laborie Medical Technologies Corp. | 3 | $146 |
| Calyxo, Inc. | 1 | $125 |
| Sumitomo Pharma America, Inc. | 1 | $113 |
| Endo Pharmaceuticals Inc. | 3 | $62 |
| Procept Biorobotics Corporation | 2 | $56 |
| Intuitive Surgical | 2 | $45 |
| Ambu Inc. | 1 | $30 |
| Angiodynamics, Inc. | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $20 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$425
- UroLift$146
- CVAC Aspiration System$125
- JELMYTO$121
- ORGOVYX$113
How this compares
$2,570 in reported general payments places this provider in the 40th percentile of 63 urology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 77 | $73,302 |
| GemtesaVibegron | 34 | $25,576 |
| Mirabegron ErMirabegron | 17 | $7,842 |
| Tamsulosin Hcl | 346 | $6,763 |
| Estradiol | 38 | $2,331 |
| Finasteride | 113 | $1,559 |
| Potassium Citrate ErPotassium Citrate | 21 | $1,270 |
| Oxybutynin Chloride ErOxybutynin Chloride | 66 | $1,235 |
| NitrofurantoinNitrofurantoin Macrocrystal | 19 | $909 |
| Testosterone Cypionate | 20 | $811 |
| Cefdinir | 22 | $207 |
| Oxycodone Hcl | 72 | $205 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 60 | $181 |
| Solifenacin Succinate | 18 | $174 |
| Ciprofloxacin Hcl | 25 | $141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $150 | $73,30277 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $113 | $25,57634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 63 urology providers in Nevada.
Other urology in Reno
- Christopher EvansReno$184K
- Eric KimReno$24K
- Nicholas HauserReno$12K
- Angelo KanellosReno$11K
- Timothy SuttleReno$8K
- Ross AndersonReno$7K
- Matthew McCormackReno$3K
- Chloe ShenkReno$3K
- Christopher TamReno$3K
- Dielle DuvalReno$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.